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Sex-based differences in the inflammatory profile
of peripheral artery disease and the association
with primary patency of lower extremity vein
bypass grafts
Jade S. Hiramoto, MD, MAS,a Christopher D. Owens, MD,a Ji Min Kim, MPH,a John Boscardin, PhD,b
Michael Belkin, MD,c Mark A. Creager, MD,d and Michael S. Conte, MD,a San Francisco, Calif; and
Boston, Mass
Objective: This study was conducted to determine if there are sex-based differences in the inflammatory phenotype of patients
undergoing lower extremity bypass (LEB) and if they correlate with clinical outcomes.
Methods: This was a retrospective analysis of a prospective cohort of 225 patients (161 men and 64 women) who underwent
autogenous vein LEB between February 2004 andMay 2008. Fasting baseline blood samples were obtained before LEB, and
the inflammatory biomarkers high-sensitivity C-reactive protein (CRP) and fibrinogen were assessed. All patients underwent
ultrasound graft surveillance. CRP levels were dichotomized at 5 mg/L and fibrinogen levels at 600 mg/dL.
Results: There were no significant differences in age, race, history of hypertension or diabetes mellitus, body mass index,
or coronary artery disease between men and women.Men were more likely to be current smokers (P .02), have a history
of hypercholesterolemia (P .02), and be taking statins (P .02). Women were more likely to present with critical limb
ischemia (P  .03) and had higher median baseline CRP levels (5.15 mg/L; interquartile range [IQR], 1.51-18.62
mg/L) than men (2.70; IQR, 1.24-6.98 mg/L; P  .02). Median follow-up was 893 days (IQR, 539-1315 days). A
multivariable Cox proportional hazardsmodel for primary vein graft patency showed a significant interaction between sex
and CRP (P  .03) and fibrinogen (P  .02). After adjustment for key covariates, primary vein graft patency was
significantly less in womenwith CRP>5mg/L compared with womenwith CRP<5mg/L (P .02). No such difference
was seen in men (P  .95). Primary graft patency was also decreased in women with fibrinogen >600 mg/dL vs women
with fibrinogen <600 mg/dL (P  .002); again, this pattern was not evident in men (P  .19).
Conclusions: Women undergoing LEB for advanced peripheral artery disease have a different inflammatory phenotype
thanmen. Elevated baseline levels of CRP and fibrinogen are associated with inferior vein graft patency in women but not
in men. These findings indicate an important interaction between sex and inflammation in the healing response of vein
grafts for LEB. Women with elevated preoperative CRP and fibrinogen levels may benefit from more intensive
postoperative graft surveillance protocols. ( J Vasc Surg 2012;56:387-95.)
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aAlthough women have lower overall rates of cardio-
vascular disease (CVD) than men until the seventh de-
cade of life,1 several population studies have demon-
strated higher age-adjusted rates of peripheral artery
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doi:10.1016/j.jvs.2012.01.059isease (PAD) in women.2-4 Also, women who undergo
ower extremity bypass (LEB) procedures appear to have
ncreased rates of wound complications and lower rates
f graft patency than men.5-7 The potential reasons for
hese poorer outcomes in women include smaller con-
uit and target vessels, more advanced disease, older age
t presentation, and a difference in the underlying state
f inflammation in women than in men.
Clinical studies have established that chronic inflamma-
ion is a strong risk factor for future atherothrombotic
isease. C-reactive protein (CRP) is an acute-phase protein
hat is elevated in individuals at high risk for myocardial
nfarction,8-10 stroke,9,11 and cardiovascular death.9 CRP
evels are also elevated in individuals with PAD,12,13 and
igher CRP levels have been associated with the risk and
rogression of PAD.14,15 Recent studies have also sug-
ested that preoperative CRP levels are predictive of ad-
erse outcomes after vascular procedures, including LEB
urgery.16-18
Fibrinogen, like CRP, is an acute-phase reactant.19 In
ddition, fibrinogen has important hemostatic properties,
s it affects platelet and red cell aggregation as well as
ndothelial function.19 As a result, high levels of fibrinogen
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August 2012388 Hiramoto et alin plasma might reduce blood flow, predispose to throm-
bosis, and enhance atherogenesis. Fibrinogen is also critical
in inflammation; in an ex-vivo study, fibrinogen was impor-
tant in mediating leukocyte adhesion to human vein
grafts.20 Fibrinogen predicts the severity of PAD17,21 and
serves as a marker for the future development of PAD.22,23
Moreover, some studies have demonstrated a positive asso-
ciation between plasma fibrinogen levels and subsequent
graft stenosis and occlusion.24,25
Several population studies have demonstrated higher
levels of CRP26,27 and fibrinogen28-30 in women compared
with men, but the clinical significance of this is not known.
Although many studies have evaluated the association be-
tween inflammatory markers and CVD outcomes, fewer
have investigated the role of inflammation and graft pa-
tency after LEB procedures. Moreover, it is unclear
whether the differences in the underlying inflammatory
profiles between men and women are important in the
outcome after LEB. To address this gap in research, our
current study investigated whether sex-based differences
exist in the baseline inflammatory markers of patients un-
dergoing LEB and if these biomarker levels are associated
with primary vein graft patency.
METHODS
Study design. This was a prospective cohort study
sponsored by the National Institutes of Health and con-
ducted at three Boston academic medical centers. The
study sought to determine the relationship between inflam-
mation and outcomes after LEB using autogenous vein
grafts. Enrollment began in February 2004 and ended in
May 2008 and included 225 patients. Details of patient
selection, inclusion and exclusion criteria, and operative
procedure have been previously described.17,31 Patients
were excluded if they were treated with a prosthetic or
nonautologous vein graft, had a history of a hypercoagula-
ble state, or had a concurrent significant event 30 days
before the index bypass operation (ie, myocardial infarc-
tion, stroke, or major surgical procedure). The study ex-
cluded patients with deep space infections of the foot or
active infection. Although patients with small ulcers or
those with dry gangrene were included in the study, those
with ulceration or gangrene requiring operative debride-
ment were excluded.
Blood collection and biomarker measurement.
Blood was collected from the fasted patient on the morning
of the LEB procedure. All samples were immediately cen-
trifuged at 3000 rpm and stored at80°C until analysis. All
samples were analyzed in batches at a core laboratory to
minimize variability. CRP levels were determined by a
high-sensitivity immunoturbidimetric assay on a Hitachi
917 analyzer (Roche-Diagnostics, Indianapolis, Ind) using
reagents and calibrators from Denka Seiken (Niigata, Ja-
pan), with a sensitivity of 0.03 mg/L. Day-to-day varia-
tions of the assay at differing concentrations were 3%.
Fibrinogen was measured using an immunonephelometric
technique on the Behring BNII analyzer (Dade Behring,
Newark, Del). Other inflammatory and metabolic bio- garkers were measured in the parent study and have been
reviously reported.31
Covariates. Race and sex were assessed by self-report.
ypertension was defined as systolic blood pressure 140
m Hg, diastolic blood pressure 90 mm Hg, or if the
atient was taking prescription medications for hyperten-
ion. Hypercholesterolemia and diabetes mellitus were
resent if the patient was taking prescribed medications or
f the diagnosis was self-reported. Active smoking was de-
ned by a positive answer to the question “Do you now
moke cigarettes?” A former smoker was defined as one
ho had smoked 100 cigarettes in his or her life but had
ot smoked in 30 days. Chronic kidney disease was defined
y an estimated glomerular filtration rate (eGFR) of 60
L/min/1.73 m2 using the Modification of Diet in Renal
isease Study equation.32 Body mass index (BMI) was
alculated as kg/m2.
CRP levels were dichotomized at 5 mg/L and fibrino-
en levels at 600 mg/dL. Although the American Heart
ssociation and Centers for Disease Control and Preven-
ion guidelines support measurement of CRP for risk strat-
fication and consider CRP 3 mg/L to be a high cardio-
ascular risk, the median value in our overall cohort was
early 3 mg/L, and the median value in women was 5
g/L. We dichotomized at CRP 5 mg/L because this
alue has previously been shown to represent a high-risk
ubgroup in a stroke cohort,33 and patients with CRP 5
g/L have impaired early vein graft luminal remodeling.34
RP5mg/L also represented the upper limit of our core
aboratory’s reference range. The standard reference values
or fibrinogen range from 150 to 450 mg/dL.19 The
edian value in our cohort was 480 mg/dL (interquartile
ange [IQR], 401-585 mg/dL). We chose to dichotomize
t 600 mg/dL because this represented the top quartile of
alues.
Operative procedure and surveillance. All patients
nderwent LEB using autogenous vein, with ipsilateral
reat saphenous vein (GSV) as the conduit of first choice.
n the absence of suitable ipsilateral vein, the contralateral
SV or arm vein was used. Routine postoperative follow-
p included a complete vascular examination by the attend-
ng surgeon and a standard duplex ultrasound examination
f the bypass graft in an accredited vascular laboratory at 1,
, 6, 9, and 12 months. After 12 months, follow-up visits
ccurred every 6 months. All clinical and graft-related
vents were recorded prospectively. Although the decision
o intervene on a failing graft was not standardized across all
urgeons, as a general rule, all patients underwent graft
ntervention for all hemodynamically significant stenoses
etected on surveillance ultrasound imaging. The type of
raft reintervention was left to the discretion of the oper-
ting surgeon.
Definition of primary patency. Loss of primary pa-
ency included any type of graft revision (balloon angio-
lasty, patch angioplasty, or interposition graft) when a
raft stenosis was detected by duplex ultrasound imaging or
R6
d
h
t
b
l
c
t
s
(
w
d
p
r
c
g
e
t
w
m
h
p
T
5
w
1
t
d
e
b
(IQR
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 2 Hiramoto et al 389other imaging modality. Loss of primary patency was also
noted if there was documentation of occlusion of the vein
graft without revision.
Statistical analysis. All statistical analyses were per-
formed using Stata/SE 10.1 software (StataCorp, College
Station, Tex). The clinical characteristics and biomarker
values of the cohort were compared for men and women
and are presented as proportions for categoric characteris-
tics and as mean  standard deviation (SD) or median and
IQR for continuous characteristics. Continuous variables
between groups were compared with the Student t-test; if
the distribution was not approximately normal, the Wil-
coxon rank-sum test was used. Proportions between groups
were compared with the Pearson 2 test. A value of P .05
was considered statistically significant.
Variable selection for multivariable models. The
bivariate associations between clinical variables, graft char-
acteristics, and biomarker levels with primary graft patency
were assessed for the overall cohort using a Cox propor-
tional hazards model. Variable selection was based on this
primary analysis. Any variable with a value of P .30 was
included in the subsequent multivariable models. Interac-
tions between sex and biomarker levels, race and biomarker
levels, sex and race, and sex and critical ischemia were also
assessed and further analyzed if the P value for interaction
was.30. A multivariable Cox proportional hazards model
was used to evaluate primary patency in men and women.
We did not include CRP and fibrinogen in the same mul-
tivariable models because it is scientifically plausible that
CRP and fibrinogen are potential mediators for one an-
other in the pathway to graft failure; hence, including both
biomarkers in the same model would result in overadjust-
ment. Indeed, CRP and fibrinogen were highly correlated
in our cohort (Pearson correlation coefficient, 0.56; P 
Table I. Demographic characteristics of the cohort
Variablea
Men
(n  161
Age, years 67.0  10
Black race 9 (5.6)
Current smoker 67 (41.6)
Diabetes 88 (54.7)
Body mass index, kg/m2 27.9  5.4
Hypertension 133 (82.6)
Coronary artery disease 90 (55.9)
eGFR, mL/min/1.73 m2 78.2  32
Hypercholesterolemia 123 (76.4)
Statin therapy 135 (83.9)
Critical ischemia 88 (54.7)
Composite vein 21 (13.0)
CRP, mg/L 2.70 (1.24-6
CRP 5 mg/L 56 (34.8)
Fibrinogen, mg/dL 498  15
Fibrinogen 600 mg/dL 38 (23.6)
CRP, C-reactive protein; eGFR, estimated glomerular filtration rate.
aContinuous data are shown as the mean  standard deviation and median.001). mESULTS
The 225 patients (28% women) were a mean age of
8 11 years and 8% were black. There were no significant
ifferences in age, race, diabetes mellitus, BMI, eGFR,
istory of hypertension, and coronary artery disease be-
ween men and women (Table I). Men were more likely to
e current smokers (P  .02), have a history of hypercho-
esterolemia (P  .02), and be on statin therapy (P  .02)
ompared with women (Table I). Women were more likely
o present with critical limb ischemia (P  .03) and had
ignificantly higher baseline CRP levels (P .02) than men
Table I).
The indication for LEB surgery in 133 patients (59%)
as critical limb ischemia, and 73 patients (32%) had evi-
ence of distal tissue loss. Bypass graft placement in 190
atients (84%) was with a single-segment GSV, whereas the
emainder underwent construction of bypass graft using
omposite GSV or arm vein. A previous ipsilateral bypass
raft had failed in 22 patients (10%). There were no differ-
nces in the type of conduit used, primary vs redo bypass, or
ype of outflow vessel (popliteal, tibial, or pedal artery) in
omen compared with men.
The median CRP level in the entire cohort was 2.98
g/L (IQR, 1.28-12.25). The median CRP level was
igher in women (5.15; IQR, 1.51-18.62 mg/L) com-
ared with men (2.70; IQR, 1.24-6.98 mg/L; P  .02;
able I). The mean fibrinogen level in the cohort was
09  176 mg/dL and was not significantly different in
omen (536 211 mg/dL) compared with men (498 
59 mg/dL; P  .16; Table I). In a multivariable analysis
hat included sex, race, age, BMI, coronary artery disease,
iabetes, statin use, critical ischemia, current smoking, and
GFR, sex (P  .04) and critical ischemia (P  .001) were
oth independently associated with baseline CRP level 5
Women
P(n  64)
69.3  12.0 .14
8 (12.5) .09
16 (25.0) .02
29 (45.3) .21
29.6  8.6 .08
57 (89.1) .23
28 (43.8) .10
70.8  39.3 .15
39 (60.9) .02
45 (70.3) .02
45 (70.3) .03
14 (21.9) .10
5.15 (1.51-18.62) .02
34 (53.1) .01
536  211 .16
21 (32.8) .16
) and categoric data as number (%).)
.4
.9
.98)
9g/L. In a similar model for fibrinogen, diabetes (P 
p
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August 2012390 Hiramoto et al.008) and critical ischemia (P  .03) were associated with
baseline fibrinogen levels 600 mg/dL.
The median follow-up was 893 days (IQR, 539-1315
days). There were 78 (35%) primary graft failures; this
occurred in 27 of 64 women (42%) and in 51 of 161 men
(32%; P .14). Of the 78 primary patency events, 26 (33%)
were graft thromboses and 52 (67%) were revisions for graft
stenosis. Men and women had similar profiles for loss of
primary patency, with 10 of 27 thrombotic events (37%) in
women and 16 of 51 thrombotic events (31%) in men (P
.61). There was no significant difference in the type of
primary patency event (stenosis vs thrombosis) by CRP
levels (P .20) or fibrinogen values (P .48) in the overall
cohort or when analyzed separately by sex. There were 35
secondary graft failures in this cohort, 11 of 64 in women
(17%) and 24 of 161 in men (15%; P  .67).
The bivariate associations between all of the variables
listed in Table I and primary graft patency were evaluated in
the entire cohort and then separately for men and women
(Table II). In the overall cohort, black race (P  .002),
diabetes mellitus (P  .07), critical ischemia (P  .009),
composite vein graft (P .06), CRP 5 mg/L (P .02),
and fibrinogen 600 mg/dL (P  .17) met the criteria
(P  .30) for inclusion into the multivariable models.
When these bivariate associations between predictors and
primary graft failure were stratified by sex, the presence of
diabetes mellitus (P  .05) and critical ischemia (P  .02)
were significantly associated with primary graft failure in
men. In women, black race (P .03), CRP 5mg/L (P
.02), and fibrinogen  600 mg/dL (P  .01) were associ-
ated with primary graft failure (Table II).
In a multivariable Cox proportional hazards model for
primary graft patency for the entire cohort, there was no
significant difference in primary vein graft patency in those
individuals with CRP5 mg/L compared with those with
CRP 5 mg/L (P  .11; Fig 1, A). However, there was a
statistically significant interaction between sex and CRP
levels (P  .03). Women with CRP 5 mg/L were signif-
Table II. Bivariate associations between predictors and pr
Variable
Men
HR (95% CI)
Age 1.00 (0.98-1.03)
Black race 2.39 (0.95-6.06)
Smoking 1.06 (0.60-1.85)
Diabetes 1.80 (1.01-3.21)
Body mass index 0.97 (0.91-1.02)
Hypertension 1.01 (0.49-2.08)
Coronary artery disease 1.08 (0.62-1.88)
Hypercholesterolemia 0.84 (0.44-1.57)
Statin therapy 0.68 (0.35-1.32)
eGFR 1.00 (0.99-1.01)
Critical ischemia 2.02 (1.14-3.63)
Composite vein 1.41 (0.67-3.03)
CRP  5 mg/L 1.35 (0.76-2.39)
Fibrinogen 600 mg/dL 0.94 (0.48-1.84)
CI, Confidence interval; CRP, C-reactive protein; eGFR, estimated glomericantly more likely to lose primary vein graft patency com- .ared with women with CRP 5 mg/L (hazard ratio
HR], 2.63; 95% confidence interval [CI], 1.15-6.02; P 
02), but no such difference was seen in men (HR, 0.98;
5% CI, 0.52-1.85; P .95; Fig 1, B and C). The findings
ere similar with respect to secondary graft patency.
omen with CRP5 mg/L were significantly more likely
o lose secondary graft patency than women with CRP 5
g/L (P  .05), but no such difference was seen in men
P  .78).
There was also a significant interaction between sex and
brinogen (P  .02). In a multivariable Cox proportional
azards model for primary graft patency, there was no
ignificant difference in primary vein graft patency in those
ith fibrinogen 600 mg/dL compared with those with
brinogen600mg/dL in the overall cohort (P .48; Fig
, A). However, women with fibrinogen 600 mg/dL
ere significantly more likely to lose primary vein graft
atency than women with fibrinogen 600 mg/dL (HR,
.09; 95% CI, 1.66-10.05; P  .002; Fig 2, B), but again,
o such difference was demonstrated in men (HR 0.62;
5% CI, 0.30-1.27; P .19; Fig 2,C). These findings were
imilar when secondary graft patency was evaluated.
omen with fibrinogen 600 mg/dL were significantly
ore likely to lose secondary vein graft patency than
omen with fibrinogen 600 mg/dL (P  .03), but no
ifference was demonstrated in men (P  .45).
The HRs for loss of primary graft patency, stratified by
ex and in separate multivariable models of CRP and fibrin-
gen, are reported in Tables III and IV, respectively. In the
RP multivariable model for primary graft patency, black
ace was significantly associated with primary graft loss in
en (HR, 2.68; 95% CI, 1.04-6.86; P  .04), whereas
lack race (HR, 3.04; 95% CI, 1.14-8.10; P  .03) and
RP  5 mg/L (HR, 2.63; 95% CI, 1.15-6.02; P  .02)
ere significantly associated with primary graft loss in
omen (Table III). In the multivariable model with fibrin-
gen, black race (HR, 2.80; 95% CI, 1.09-7.22; P  .03)
nd critical ischemia (HR, 1.87; 95% CI, 1.00-3.50; P 
patency, stratified by sex
P
Women
PHR (95% CI)
.72 1.00 (0.97-1.04) .90
.07 2.80 (1.11-7.06) .03
.85 0.94 (0.39-2.25) .89
.05 1.17 (0.53-2.57) .70
.22 1.01 (0.97-1.06) .57
.97 3.18 (0.43-23.54) .26
.79 1.64 (0.75-3.61) .22
.58 2.36 (0.94-5.91) .07
.25 1.07 (0.45-2.56) .88
.66 1.00 (0.99-1.01) .74
.02 1.42 (0.59-3.40) .43
.36 1.93 (0.85-4.36) .12
.30 2.64 (1.16-6.02) .02
.87 2.87 (1.29-6.38) .01
tration rate; HR, hazard ratio.imary05) were significantly associated with primary graft loss in
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Volume 56, Number 2 Hiramoto et al 391men, whereas in women, black race (HR, 4.22; 95% CI,
1.53-11.64; P .005) and fibrinogen600 mg/dL (HR,
4.09; 95% CI, 1.66-10.05; P  .002) were significantly
associated with primary graft loss (Table IV).
DISCUSSION
This prospective study of patients with advanced PAD
undergoing LEB with autogenous vein demonstrated that
elevated baseline levels of CRP and fibrinogen were each
associated with graft failure in women but not in men. We
found a significant interaction between sex and both CRP
and fibrinogen in the primary patency rate of LEB grafts,
suggesting a different underlying inflammatory profile in
men and women who present with severe PAD.
In our study, women had significantly higher base-
line levels of CRP compared with men. This is not
surprising, as several large cohort studies have demon-
strated differences in CRP levels by both sex and race.
The Multiethnic Study of Atherosclerosis (MESA) co-
hort of 6814 men and women aged 45 to 84 years found
substantially higher median CRP levels in women than in
men, despite accounting for estrogen use, BMI, and
Fig 1. A,Multivariable Cox regression curves show prim
(C) men undergoing lower extremity bypass surgery withother confounding variables.26 This sex difference was paintained across all ethnic subgroups. In the Dallas
eart Study, women had significantly higher CRP levels
han men, and black patients had significantly higher
evels than white patients.27 These findings remained
ignificant after adjustment for BMI and traditional car-
iovascular risk factors, as well as after exclusion of
ndividuals taking statins and estrogens. Our study pop-
lation is limited with regards to racial diversity; there-
ore, we were unable to examine the potential synergies
etween sex, race, and inflammation. Although men and
omen differed in several baseline factors, it is notewor-
hy that female sex was independently correlated with
RP level even after adjustment for multiple covariates.
Previous studies have demonstrated CRP to indepen-
ently predict future CVD events in both men and wo-
en.8-10 However, subgroup observations from both the
ardiovascular Health Study (CHS) and the Rural Health
romotion Project demonstrated the risks of vascular dis-
ase associated with CRP were greater for women than for
en.35 Similarly, in the Women’s Health Study, the ad-
usted relative risk for either myocardial infarction or stroke
n women with the highest quartile of CRP was 5.5 com-
raft patency for (A) all patients, for (B) women, and for
genous vein based on C-reactive protein (CRP) values.ary gared with 2.8 in men participating in the Physicians’
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August 2012392 Hiramoto et alHealth Study.8,9 Although CRP is a strong and indepen-
dent risk factor for adverse cardiovascular outcomes in men
and women, these findings suggest that women with ele-
vated CRP may be at a relatively higher risk for a cardiovas-
cular event compared with men. Few studies have been
performed examining the association between CRP and
LEB graft patency,16-18 and none of these examined results
by sex.
Recent work suggests there may be an important rela-
tionship between systemic inflammation and the early re-
Fig 2. Multivariable Cox regression curves for primary
men undergoing lower extremity bypass surgery with au
Table III. Multivariable Cox proportional hazards model
(CRP), stratified by sex
Variable
Men
HR (95% CI)
Black race 2.68 (1.04-6.86)
Diabetes 1.64 (0.88-3.04)
Composite vein 1.21 (0.56-2.64)
Critical ischemia 1.72 (0.88-3.34)
CRP 5 mg/L 0.98 (0.52-1.85)
CI, Confidence interval; HR, hazard ratio.modeling changes in LEB grafts; specifically, the early a1-month) venous dilation response to arterialization ap-
ears to be impaired in patients with elevated baseline CRP
evels.34 This suggests a possible uncoupling between he-
odynamic stress and vessel remodeling. If true, such
mpaired early remodeling may likely have greater clinical
mpact in the setting of smaller conduit vessels. In this
tudy, we found that the divergence of loss of primary
atency, by preoperative biomarker level, primarily oc-
urred within the first year, further supporting this idea.
his hypothesis will need to be formally examined in future
patency for (A) all patients, (B) for women, and (C) for
ous vein, based on fibrinogen levels.
rimary graft patency, including C-reactive protein
P
Women
PHR (95% CI)
.04 3.04 (1.14-8.10) .03
0.12 1.10 (0.47-2.57) 0.82
0.63 1.85 (0.78-4.39) 0.16
0.11 1.16 (0.48-2.83) 0.74
0.95 2.63 (1.15-6.02) .02graftfor pnd ongoing studies.
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Volume 56, Number 2 Hiramoto et al 393Fibrinogen levels also differ by sex and race and have
been reported to be higher in women than in men28-30 and
in blacks than in whites.28-30 Fibrinogen levels increase
with age, smoking, body size, diabetes, fasting serum insu-
lin, low-density lipoprotein cholesterol, and meno-
pause.28-30 A meta-analysis of fibrinogen as a CVD risk
factor identified six prospective epidemiologic studies, all of
which demonstrated that fibrinogen was associated with
subsequent myocardial infarction or stroke.36 Although
fibrinogen appears to be a strong CVD risk factor in both
men and women, it is unclear from any of these previous
studies whether there is a differential association in women
compared with men.
We found a strong interaction between sex and fibrin-
ogen with regards to vein graft patency in our cohort. A
high fibrinogen level was significantly associated with graft
failure in women but not in men. Fibrinogen plays an
important role in patients with PAD. In the CHS cohort,
ankle-brachial index levels were inversely correlated with
fibrinogen levels.37 Plasma fibrinogen has also been shown
to be a predictor of the development22,23 and severity of
PAD.17,21 In studies in PAD patients, fibrinogen levels
were found to be the strongest independent predictor of
death from coronary disease38 and all-cause cardiovascular
mortality.39 There are fewer data reporting the association
between fibrinogen level and outcomes after lower extrem-
ity revascularization. Two reports evaluating patients with
lower extremity vein grafts demonstrated elevated fibrino-
gen levels were associated with vein graft stenoses24 and
graft occlusion.25 In contrast, a study that evaluated 57
patients undergoing infrainguinal arterial reconstruction
with saphenous vein narrowly failed to demonstrate a sta-
tistically significant association between fibrinogen levels
and graft failure.40 It is possible that a type II error occurred
or, perhaps, that an unidentified interaction contributed to
the overall negative results of the study. To our knowledge,
no studies have evaluated the association between fibrino-
gen and LEB graft patency separately for women and men.
There are several studies that suggest that women have
higher rates of graft failure and increased rates of wound
complications after LEB graft procedures, but clear predis-
posing factors have not been identified.5-7 It is possible that
women who present with advanced PAD have an underly-
ing inflammatory phenotype that puts them at a dispropor-
Table IV. Multivariable Cox proportional hazards model
by sex
Variable
Men
HR (95% CI)
Black race 2.80 (1.09-7.22)
Diabetes 1.85 (0.98-3.50)
Composite vein 1.13 (0.51-2.46)
Critical ischemia 1.87 (1.00-3.50)
Fibrinogen 600 mg/dL 0.62 (0.30-1.27)
CI, Confidence interval; HR, hazard ratio.tionately higher risk for subsequent graft failure compared With men. Measurement of both CRP and plasma fibrino-
en in women before revascularization may identify those
ho are at highest risk for graft failure and could potentially
mprove results either by aggressive risk factor modification
r a more intensive graft surveillance schedule. Prospective
tudies are needed to validate the use of these biomarkers
or risk prediction in this population.
This study has several limitations. Our series of pa-
ients had advanced PAD, including a large proportion
ith critical limb ischemia. Also, all patients were treated
ith a vein conduit. Therefore, our results may not be
eneralizable to those with more mild disease or in those
ho undergo LEB with a prosthetic graft. We dichoto-
ized CRP at 5 mg/L and fibrinogen at 600 mg/dL,
ither or both of which may not be the ideal cut points.
RP and fibrinogen were not included together in the
ame multivariable Cox model, and hence we could not
ssess whether each biomarker was independently asso-
iated with graft failure. In addition, only preoperative
evels of inflammatory markers were available in this
tudy, and hence we could not evaluate whether changes
n CRP and fibrinogen levels after LEB were associated
ith graft failure. The modest size and diversity of the
tudy population also limit its generalizability. The find-
ngs should be considered hypothesis-generating and
rovide impetus for further studies examining the inter-
ction of gender and inflammation in peripheral revascu-
arization.
ONCLUSIONS
Women undergoing LEB for advanced PAD have a
ifferent inflammatory phenotype than men. Elevated
aseline levels of CRP and fibrinogen are associated with
nferior vein graft patency in women but not in men. These
ndings indicate an important interaction between sex and
nflammation in the healing response of vein grafts for LEB.
omen with elevated preoperative CRP and fibrinogen
evels may benefit from more intensive postoperative graft
urveillance protocols.
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We also analyzed secondary graft patency in this cohort and
the findings were similar to those for primary graft patency.
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Dr Michelle Mueller (Salt Lake City, Utah). I would like to
thank the program committee for inviting me to be a discussant.
Congratulations to Dr Hiramoto on a very nice presentation and
the authors on an excellent study and paper.
Many of us have the impressing that women with peripheral
artery disease do more poorly than men. The question is why, and
can we do anything to improve their surgical outcomes. In this
prospective study, the authors show us that high-sensitivity C-
reactive protein (CRP) and fibrinogen are not only elevated in
women at baseline when compared to men, but those women with
elevated CRP or fibrinogen have decreased primary graft patency.
A few questions and comments:
In the paper you state there are no differences in the outflow
vessels (popliteal versus tibial versus pedal). However, there were
significantly more women with critical limb ischemia than men. Is
there a trend towards more infrapopliteal bypasses in women in
general, and more specifically in those with elevated inflammatory
markers?
Dr Jade S. Hiramoto. Thank you for reviewing our manu-
script and for your kind comments. Indeed, there were significantly
more womenwith critical limb ischemia in this cohort compared to
men. However, there were no significant differences in the target
outflow vessels by sex. In both men and women, about half
underwent a bypass graft to the popliteal artery, and the other half
underwent a bypass graft to either a tibial or pedal vessel. There was
no statistically significant difference, nor was there a trend toward
more infrapopliteal bypasses in women. Those patients with either
CRP 5 mg/L or fibrinogen 600 mg/dL were more likely to
undergo an infrapopliteal bypass compared to those with CRP5
mg/L or fibrinogen 600 mg/dL, but this was true for both the
men and women in this cohort.
Dr Mueller. Does the decreased primary graft patency in
women with elevated CRP or fibrinogen correlate with graft
thrombosis or limb loss, or are there just more interventions on
grafts in these groups?
Dr Hiramoto. The discussant raises an important question.
Of the 78 primary patency events, 26 (33%) were due to graft
thrombosis and 52 (67%) were revisions for graft stenosis. Both
men and women had similar profiles for loss of primary patency—
37% of the primary patency events were graft thrombosis in
women, and 31% were graft thrombosis events in men. There was
no significant difference in the type of primary patency event
(thrombosis or stenosis) based on CRP or fibrinogen values. This
was true when analyzed in the overall cohort and when separately
analyzed by sex.omen with CRP5 mg/L were significantly more likely to lose
econdary graft patency compared to women with CRP5mg/L,
nd women with fibrinogen600 mg/dL were significantly more
ikely to lose secondary graft patency compared to women with
brinogen600mg/dL. These findings were not seen in the men
n this cohort.
Dr Mueller. Would a more intensive graft surveillance pro-
ram decrease graft thrombosis and improve limb salvage?
DrHiramoto. It is difficult to know whether a more intensive
raft surveillance program would decrease the graft thrombosis
ate. Most of the losses of primary graft patency occurred within
he first year, and we performed duplex ultrasound examination of
he bypass grafts at 1, 3, 6, 9, and 12 months postoperatively.
ased on the findings in this study, one might consider increasing
he frequency of this surveillance in a higher risk patient, for
nstance, a woman with CRP 5 mg/L or fibrinogen 600
g/dL. However, it is unclear whether this would change the
verall outcome.
Dr Mueller. Finally, you recommend aggressive risk factor
odification. Would you delay bypass in women with critical limb
schemia and elevated inflammatory markers for risk factor modi-
cation, and what modifications would you recommend? With our
urrent knowledge regarding these inflammatory markers, are we
ot already encouraging smoking cessation and aggressively treat-
ng patients with statins? Perhaps we are failing to recognize
eripheral artery disease early in women and also failing to aggres-
ively medically mange them.
Dr Hiramoto. Because of the overall size of the cohort and
elatively small numbers of women, I think that one should con-
ider the findings from our study hypothesis-generating. I think it
rovides important background information for future studies to
urther evaluate this interaction between sex and inflammation.We
elieve that all at-risk individuals should stop smoking and be
reated with statins, yet 37% of our cohort were still smoking, and
0% of the women in this cohort were not on statin therapy. So,
here is still room for improvement. At this point in time, I would
ot recommend delaying bypass grafting in women with critical
imb ischemia and elevated inflammatory markers for risk factor
odification without further confirmatory data. Finally, I agree
ith Dr. Mueller—epidemiologic studies have demonstrated that
eripheral artery disease prevalence is equal (if not higher) in
omen compared to men. We are not doing a good enough job at
ecognizing peripheral artery disease early in women, and hence,
e are failing to provide the appropriate aggressive medical man-
gement.
